Dr. Pol Boudes to leave CymaBay Therapeutics — 4 insights

Clinical-stage biopharmaceutical company CymaBay Therapeutics will lose its CMO Pol Boudes, MD, who is leaving the company on his own accord.

Advertisement

What you should know:

1. Dr. Boudes will resign Sept. 30.

2. CymaBay began searching for his replacement.

3. Gideon Hirschfield, MD, will provide medical and clinical support while the company searches for a fulltime replacement.

4. CymaBay is developing treatments for liver and other chronic diseases.

More articles on surgery center:
ASC supply chain tip of the day: Rely on data
Prevent cross contamination with single sterile IV start kits
Medline to Expand Southeast Distribution with New North Carolina Center

Advertisement

Next Up in GI & Endoscopy

  • Renton, Wash.-based Providence has re-opened its North Coast Surgery Center in Oceanside, Calif., the Times Standard reported Feb. 5.  The…

  • Gastroenterology is rapidly transforming as health systems invest in outpatient digestive care, private equity-backed platforms expand and new technology reshapes…

  • AI’s early gains in gastroenterology are showing up in some of the most workflow-heavy parts of endoscopy — polyp detection,…

Advertisement

Comments are closed.